Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist Xolremdi ...

Stay up to date on all meme stocks with Benzinga Pro, your go-to stock market research platform with real-time news and actionable insights. Many trends and fads in investing capture the attention of ...

Executive Editor David Carnoy has been a leading member of CNET's Reviews team since 2000. He covers the gamut of gadgets and is a notable reviewer of mobile accessories and portable audio products, ...

The biggest stories of the day delivered to your inbox.